# Pretomanid in Adults With Hepatic Impairment

> **NCT02422524** · PHASE1 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 14 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** PA-824

## Key facts

- **NCT ID:** NCT02422524
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-29
- **Primary completion:** 2023-08-26
- **Final completion:** 2023-11-17
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The TB hepatic pretomanid PK trial is closed to enrollment. There is no possibility of enrolling and completing the CSR before November 2024.
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422524, "Pretomanid in Adults With Hepatic Impairment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02422524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*